In this study the regulation of the release of noradrenaline by P2 receptors was investigated in hippocampus slices preincubated with [ 3 H]NA. Electrical field stimulation (EFS; 2 Hz, 240 shock, 1 ms) enhanced the release of noradrenaline in a [Ca] o -dependent manner. In contrast, the excess release in response to ischemic-like conditions (combined oxygen and glucose deprivation) was [Ca] oindependent. The Na + channel blocker tetrodotoxin (1-3 μM) abolished both EFS-evoked and in vitro ischemiaevoked release of tritium. The P2 receptor agonists ATP, ADP and 2-MeSADP concentration-dependently decreased the tritium overflow with the potency order of ADP > 2-MeSADP > ATP. The inhibition by ATP (300 μM) was prevented by the P2 receptor antagonist PPADS (30 μM), by the P2Y 1 receptor antagonist MRS2179 (10 μM) and by the P2Y 12/13 receptor antagonist 2-MeSAMP (10 μM). Under ischemic-like conditions the P2X 1 receptor antagonist PPNDS (1 μM) inhibited the outflow of [ 3 H]NA, whereas MRS2179 (10 μM) significantly increased the tritium outflow. PPADS and 2-MeSAMP did not affect ischemia-evoked [ 3 H]NA efflux. RT-PCR analysis revealed that mRNA encoding P2Y 12 and P2Y 13 receptor subunits were expressed in the brainstem including locus coeruleus. The pharmacological profile of the underlying receptor subtype resembles the P2Y 1 and P2Y 13 receptor phenotype, and the endogenous activation of P2X 1 and P2Y 1 receptors contribute to the modulation of noradrenaline efflux upon ischemic-like conditions.
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